Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with vitiligo

Genetics and Molecular Research

Volumn 12, Issue 3, 2013, Pages 2196-2204

  Al Harthi, F ^a   Zouman, A ^a   Arfin, M ^a   Tariq, M ^a   Al Asmari, A ^a  

^a Prince Sultan Military Medical City   (Saudi Arabia)

Author keywords

Polymorphism; Saudi; Tumor necrosis factor; Vitiligo

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RISK FACTOR; SAUDI ARABIA; TUMOR NECROSIS FACTOR ALPHA GENE; TUMOR NECROSIS FACTOR BETA GENE; VITILIGO;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRONS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SAUDI ARABIA; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO;

EID: 84880101366     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.July.8.1     Document Type: Article

References (41)

1. Abanmi A, Al Harthi F, Al Bagami R, Al Assaf S, et al. (2006). Association of HLA loci alleles and antigens in Saudi patients with vitiligo. Arch. Dermatol. Res. 298: 347-352.
2. Abraham LJ and Kroeger KM (1999). Impact of the-308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J. Leukoc. Biol. 66: 562-566.
3. Abraham LJ, French MA and Dawkins RL (1993). Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin. Exp. Immunol. 92: 14-18.
4. Aguillón JC, Cruzat A, Cuenca J and Cuchacovich M (2002). Tumor necrosis factor alpha genetic polymorphism as a risk factor in disease. Rev. Med. Chil. 130: 1043-1050.
5. Al-Rayes H, Al-Swailem R, Albelawi M, Arfin M, et al. (2011). TNF-a and TNF-β gene polymorphism in saudi rheumatoid arthritis patients. Clin. Med. Insights Arthritis Musculoskelet. Disord. 4: 55-63.
6. Alkhateeb A and Qarqaz F (2010). Genetic association of NALP1 with generalized vitiligo in Jordanian Arabs. Arch. Dermatol. Res. 302: 631-634.
7. Braun N, Michel U, Ernst BP, Metzner R, et al. (1996). Gene polymorphism at position-308 of the tumor-necrosis-factoralpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci. Lett. 215: 75-78.
8. Campanati A, Giuliodori K, Ganzetti G, Liberati G, et al. (2010). A patient with psoriasis and vitiligo treated with etanercept. Am. J. Clin. Dermatol. 11 (Suppl 1): 46-48.
9. Chen G, Wilson R, Wang SH, Zheng HZ, et al. (1996). Tumour necrosis factor-alpha (TNF-a) gene polymorphism and expression in pre-eclampsia. Clin. Exp. Immunol. 104: 154-159.
10. Cuenca J, Pérez CA, Aguirre AJ, Schiattino I, et al. (2001). Genetic polymorphism at position-308 in the promoter region of the tumor necrosis factor (TNF): implications of its allelic distribution on susceptibility or resistance to diseases in the Chilean population. Biol. Res. 34: 237-241.
11. Gauthier Y, Cario-Andre M, Lepreux S, Pain C, et al. (2003). Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br. J. Dermatol. 148: 95-101.
12. Gavalas NG, Akhtar S, Gawkrodger DJ, Watson PF, et al. (2006). Analysis of allelic variants in the catalase gene in patients with the skin depigmenting disorder vitiligo. Biochem. Biophys. Res. Commun. 345: 1586-1591.
13. Huang CL, Nordlund JJ and Boissy R (2002). Vitiligo: a manifestation of apoptosis? Am. J. Clin. Dermatol. 3: 301-308.
14. Karaca N, Ozturk G, Gerceker BT, Turkmen M, et al. (2013). TLR2 and TLR4 gene polymorphisms in Turkish vitiligo patients. J. Eur. Acad. Dermatol. Venereol. 27: e85-90.
15. Kim NH, Jeon S, Lee HJ and Lee AY (2007). Impaired PI3K/Akt activation-mediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. J. Invest. Dermatol. 127: 2612-2617.
16. Kim NH, Torchia D, Rouhani P, Roberts B, et al. (2011). Tumor necrosis factor-alpha in vitiligo: direct correlation between tissue levels and clinical parameters. Cutan. Ocul. Toxicol. 30: 225-227.
17. Lu LY, Cheng HH, Sung PK, Tai MH, et al. (2005). Tumor necrosis factor-beta +252A polymorphism is associated with systemic lupus erythematosus in Taiwan. J. Formos. Med. Assoc. 104: 563-570.
18. Martínez-Esparza M, Jimenez-Cervantes C, Solano F, Lozano JA, et al. (1998). Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. Eur. J. Biochem. 255: 139-146.
19. Messer G, Spengler U, Jung MC, Honold G, et al. (1991). Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J. Exp. Med. 173: 209-219.
20. Moretti S, Spallanzani A, Amato L, Hautmann G, et al. (2002). New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 15: 87-92.
21. Moretti S, Fabbri P, Baroni G, Berti S, et al. (2009). Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol. Histopathol. 24: 849-857.
22. Namian AM, Shahbaz S, Salmanpoor R, Namazi MR, et al. (2009). Association of interferon-gamma and tumor necrosis factor alpha polymorphisms with susceptibility to vitiligo in Iranian patients. Arch. Dermatol. Res. 301: 21-25.
23. Nemec P, Pavkova-Goldbergova M, Stouracova M, Vasku A, et al. (2008). Polymorphism in the tumor necrosis factoralpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin. Rheumatol 27: 59-65.
24. Ongenae K, Van Geel N and Naeyaert JM (2003). Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 16: 90-100.
25. Qidwai T and Khan F (2011). Tumour necrosis factor gene polymorphism and disease prevalence. Scand. J. Immunol. 74: 522-547.
26. Rigopoulos D, Gregoriou S, Larios G, Moustou E, et al. (2007). Etanercept in the treatment of vitiligo. Dermatology 215: 84-85.
27. Schallreuter KU, Levenig C, Kuhnl P, Loliger C, et al. (1993). Histocompatibility antigens in vitiligo: Hamburg study on 102 patients from northern Germany. Dermatology 187: 186-192.
28. Sehgal VN and Srivastava G (2007). Vitiligo: compendium of clinico-epidemiological features. Indian J. Dermatol. Venereol. Leprol. 73: 149-156.
29. Shajil EM, Chatterjee S, Agrawal D, Bagchi T, et al. (2006). Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. Indian J. Exp. Biol. 44: 526-539.
30. Sharma R, Sharma CL and Mahajan A (2008). Biological agents targeting beyond TNF-alpha. Indian J. Crit. Care Med. 12: 181-189.
31. Spritz RA (2012). Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J. Invest. Dermatol. 132: 268-273.
32. Svejgaard A, Platz P and Ryder LP (1983). HLA and disease 1982-a survey. Immunol. Rev. 70: 193-218.
33. Swope VB, Abdel-Malek Z, Kassem LM and Nordlund JJ (1991). Interleukins 1 alpha and 6 and tumor necrosis factoralpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J. Invest. Dermatol. 96: 180-185.
34. Taieb A (2012). Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res. 25: 9-13.
35. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, et al. (2003). Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res. 16: 254-260.
36. Watanabe E, Buchman TG, Hirasawa H and Zehnbauer BA (2010). Association between lymphotoxin-a (tumor necrosis factor-β) intron polymorphism and predisposition to severe sepsis is modified by gender and age. Crit. Care Med. 38: 181-193.
37. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, et al. (1997). Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349: 170-173.
38. Wilson AG, de Vries N, Pociot F, di Giovine FS, et al. (1993). An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 177: 557-560.
39. Wilson AG, Symons JA, McDowell TL, McDevitt HO, et al. (1997). Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 94: 3195-3199.
40. Yazici AC, Erdal ME, Kaya TI, Ikizoglu G, et al. (2006). Lack of association with TNF-alpha-308 promoter polymorphism in patients with vitiligo. Arch. Dermatol. Res. 298: 46-49.
41. Zhang XJ, Chen JJ and Liu JB (2005). The genetic concept of vitiligo. J. Dermatol. Sci. 39: 137-146.